Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: Current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-γ

Journal of Infectious Diseases

Volumn 185, Issue 10, 2002, Pages 1490-1501

  Hübel, Kai ^a,b   Dale, David C ^a   Liles, W Conrad ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

CHILL; DRUG EFFICACY; EOSINOPHILIA; ERYTHEMA; FATIGUE; FEVER; HEADACHE; HUMAN; INFECTION; MUSCULOSKELETAL DISEASE; MYALGIA; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALS; CHILLS; CLINICAL TRIALS; COMMUNICABLE DISEASES; DISEASE MODELS, ANIMAL; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEADACHE; HUMANS; INTERFERON TYPE II; MACROPHAGE COLONY-STIMULATING FACTOR; PAIN; PHAGOCYTES; THROMBOCYTOPENIA;

EID: 0037093973     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/340221     Document Type: Review

References (177)

1. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor
2. Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells
3. Hematopoietic growth factors: Biology and clinical application
4. Nomenclature and biologic significance of cytokines involved in inflammation and the host immune response
5. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization
6. Endogenous hematopoietic growth factors in neutropenia and infection
7. Production of colony-stimulating factors (CSFs) during infection: Separate determinations of macrophage-, granulocyte-, granulocyte-macrophage-, and multi-CSFs
8. Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis
9. Recombinant human TNF-alpha stimulates production of granulocyte colony-stimulating factor
10. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha
11. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay
12. Increased serum levels of granulocyte colony-stimulating factor in patients with severe congenital neutropenia
13. Increased cytokine levels and abnormal response of myeloid progenitor cells to granulocyte colony-stimulating factor in a case of severe congenital neutropenia: In vitro effects of stem cell factor
14. Serum granulocyte colony-stimulating factor levels in patients with chronic neutropenia of childhood: Modulation of G-CSF levels by myeloid precursor cell mass
15. Serum granulocyte colony-stimulating factor levels are not increased in patients with autoimmune neutropenia of infancy
16. Review: Granulocyte colony-stimulating factor - Role and relationships in infectious diseases
17. Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the nonneutropenic host: An overview
18. Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice
19. Effects of granulocyte colony-stimulating factor in a nonneutropenic rodent model of Escherichia coli peritonitis
20. Granulocyte colony-stimulating factor and antibiotics in the prophylaxis of a murine model of polymicrobial peritonitis and sepsis
21. G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects
22. Granulocyte colony-stimulating factor worsens the outcome of experimental Klebsiella pneumoniae pneumonia through direct interaction with the bacteria
23. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor
24. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia
25. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia
26. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias
27. Contrasting effects of recombinant human granulocyte-macrophage colony-stimulating factor (CSF) and granulocyte CSF treatment on the cycling of blood elements in childhood-onset cyclic neutropenia
28. G-CSF in the long-term treatment of cyclic neutropenia and chronic idiopathic neutropenia in adult patients
29. Safety of long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia
30. Severe chronic neutropenia: Pathophysiology and therapy
31. Recombinant granulocyte colony-stimulating factor (rG-CSF): A review of its pharmacological properties and prospective role in neutropenic conditions
32. Granulocyte and granulocyte-macrophage colony-stimulating factors
33. Potential role of colony-stimulating factors in the prevention and treatment of infectious diseases
34. Severe congenital neutropenia unresponsive to G-CSF
35. Combined corticosteroid/granulocyte colony-stimulating factor (G-CSF) therapy in the treatment of severe congenital neutropenia unresponsive to G-CSF: Activated glucocorticoid receptors synergize with G-CSF signals
36. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia
37. Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
38. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
39. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer
40. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy
41. Filgrastim in patients with chemotherapy-induced febrile neutropenia: A double-blind, placebo-controlled trial
42. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors
43. Granulocyte colony-stimulating factor in established febrile neutropenia: A randomized study of pediatric patients
44. The medical course of cancer patients with fever and neutropenia: Clinical identification of a low-risk subgroup at presentation
45. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule
46. Performance status assessment in cancer patients: An inter-observer variability study
47. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial
48. Filgrastim (r-metHuG-CSF): The first 10 years
49. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases
50. Role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of patients with HIV infection
51. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: The role of granulocyte colony-stimulating factor
52. Use of cytokines in human immunodeficiency virus-infected patients: Colony-stimulating factors, erythropoietin, and interleukin-2
53. + T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy; results from randomized, placebo-controlled trial
54. Granulocyte colony-stimulating factor treatment in AIDS patients
55. Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS
56. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: Results of a randomized multicenter controlled trial
57. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine
58. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection
59. Combination treatment with azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection
60. Hematologic abnormalities in AIDS
61. The bone marrow in AIDS: A histologic, hematologic, and microbiologic study
62. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors
63. Hematologic effects of AIDS therapies
64. Suppression of in vitro hematopoiesis following human immunodeficiency virus infection
65. Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus
66. Individual cell analysis of the cytokine repertoire in human immunodeficiency virus-1-infected monocyte/macrophages by a combination of immunocytochemistry and in situ hybridization
67. Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome
68. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection
69. Clinical significance of neutropenia in patients with the human immunodeficiency virus
70. Neutropenia and bacterial infection in acquired immunodeficiency syndrome
71. Neutropenia is associated with bacteremia in patients infected with the human immunodeficiency virus
72. Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type 1 and partial reversal after in vitro exposure to granulocyte-macrophage colony-stimulating factor
73. Polymorphonuclear neutrophils from human immunodeficiency virus-infected patients show enhanced activation, diminished fMLP-induced L-selectin shedding, and an impaired oxidative burst after cytokine priming
74. Depressed neutrophil superoxide production in human immunodeficiency virus infection
75. Blood monocyte and neutrophil functions in the acquired immunodeficiency syndrome
76. Impairment of neutrophil bactericidal capacity in patients with AIDS
77. Impaired neutrophil function in patients with AIDS and AIDS-related complex: A comprehensive evaluation
78. Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on the bactericidal functions of neutrophils
79. Systemic fungal infections in patients with hematologic malignancies: Indications and limitations of the antifungal armamentarium
80. Interactions of phagocytic cells with Candida and other opportunistic fungi
81. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens
82. Effect of granulocyte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole
83. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma-interferon
84. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia
85. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia
86. Randomized placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection
87. Perioperative treatment with granulocyte colony-stimulating factor (G-CSF) in patients with esophageal cancer stimulates granulocyte function and reduces infectious complications after esophagectomy
88. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary hemostasis
89. Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival
90. Granulocyte-macrophage colony-stimulating factor: Pleiotropic cytokine with potential clinical usefulness
91. The human gene encoding GM-CSF is at 5q21-q32, the chromosome region deleted in the 5q- anomaly
92. Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis
93. Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers
94. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome
95. GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection
96. Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice
97. The ability of recombinant murine granulocyte-macrophage colony-stimulating factor to protect neonatal rats from septic death due to Staphylococcus aureus
98. Effect of granulocyte-macrophage colony-stimulating factor on sepsis-induced organ injury in rats
99. Prediction of the role of granulocyte-macrophage colony-stimulating factor in animals and man from in vitro results
100. Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice
101. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression
102. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: A double-blind, placebo-controlled study in children
103. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia
104. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia
105. Hematopoietic growth factors in autologous transplantation
106. Fungal infections in cancer patients: An international autopsy survey
107. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infections
108. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophages and synergy with fluconazole
109. Killing of Mycobacterium avium by neutrophils and monocytes from AIDS patients treated with recombinant granulocyte-macrophage colony-stimulating factor
110. Granulocyte-macrophage colony-stimulating factor augments phagocytosis of Mycobacterium avium complex by human immunodeficiency virus type 1 - Infected monocytes/macrophages in vitro and in vivo
111. Granulocyte-macrophage colony-stimulating factor inhibits HIV-1 replication in monocyte-derived macrophages
112. Molecular cloning of a complementary DNA encoding human macrophage - Specific colony stimulating factor (CSF-1)
113. Macrophage function activating cytokines: Potential clinical application
114. Use of macrophage colony-stimulating factor in the treatment of fungal infections
115. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus
116. Endogenous macrophage CSF production is associated with viral replication in HIV-1 - Infected human monocyte-derived macrophages
117. Macrophage colony-stimulating factor antagonists inhibit replication of HIV-1 in human macrophages
118. Macrophage colony-stimulating factor in murine candidiasis: Serum and tissue levels during infection and protective effect of exogenous administration
119. Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection
120. Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat
121. In vivo hematologic effects of recombinant human macrophage colony-stimulating factor
122. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections
123. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor
124. Interferon-gamma in the management of infectious diseases
125. Interferon-gamma and host antimicrobial defense: Current and future clinical applications
126. Immunomodulatory approaches to augment phagocyte-mediated host defense for treatment of infectious diseases
127. Multiple defects of immune cell function in mice with disrupted gamma-interferon genes
128. Immune response in mice that lack the interferon-gamma receptor
129. Recombinant interferon-gamma enhances resistance to acute disseminated Candida albicans infection in mice
130. Interferon-gamma and tumor necrosis factor-α protect mice from invasive aspergillosis
131. Intratracheal interferon-gamma augments pulmonary defenses in experimental legionellosis
132. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis
133. A controlled trial of interferon-gamma to prevent infection in chronic granulomatous disease
134. Interferon-gamma in the management of chronic granulomatous disease
135. Safety and effectiveness of long-term interferon-gamma therapy in patients with chronic granulomatous disease
136. Clinical and immunologic aspects of the hyperimmunoglobulin E syndrome
137. Hyper IgE syndrome with recurrent infections - An autosomal dominant multisystem disorder
138. Raised serum-IgE levels and defective neutrophil chemotaxis in three children with eczema and recurrent bacterial infections
139. Defect in neutrophil granulocyte chemotaxis in Job syndrome of recurrent "cold" staphylococcal abscesses
140. Defective in vitro production of gamma-interferon and tumor necrosis factor-alpha by circulating T cells from patients with the hyper-immunoglobulin E syndrome
141. Defective interleukin-12/interferon-gamma pathway in patients with hyperimmunoglobulinemia E syndrome
142. Use of recombinant human interferon-alpha to enhance neutrophil chemotactic responses in Job syndrome of hyper-immunoglobulin E and recurrent infections
143. Recombinant human interferon-gamma treatment of patients with Job's syndrome of hyperimmunoglobulinemia E and recurrent infections
144. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon-gamma
145. Treatment of visceral leishmaniasis with pentavalent antimony and interferon-gamma
146. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol
147. Aerosolized interferon-gamma for Mycobacterium avium-complex lung disease
148. Cytokine therapy of mycobacterial infections
149. Immunotherapy of mycobacterial infections
150. In vivo effects of recombinant human granulocyte colony-stimulating factor on normal neutrophil function and membrane effector molecule expression
151. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: Comparisons and potential for use in the treatment of infections in nonneutropenic patients
152. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures
153. + cell counts and the collection of peripheral blood stem cells
154. A comparative trial of granulocyte colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers
155. Neutrophil transfusions: Kinetics and functions of neutrophils mobilized with granulocyte colony-stimulating factor and dexmethasone
156. Blood counts in healthy donors 1 year after the collection of granulocyte-colony-stimulating factor-mobilized progenitor cells and the result of a second mobilization and collection
157. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors
158. Collection of two peripheral blood stem cell concentrates from healthy donors
159. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation
160. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone
161. Safety and long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia
162. Pulmonary toxicity during granulocyte colony-stimulating factor administration and neutrophils
163. Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: Survey in Japan 1991-96
164. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs
165. Unusual adverse events following peripheral blood stem cell (PBSC) mobilisation using granulocyte colony stimulating factor (G-CSF) in healthy donors
166. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): Occurrence in an allogeneic donor of peripheral blood stem cells
167. Spontaneous rupture of spleen during peripheral blood stem-cell mobilization in a healthy donor
168. Allogeneic blood stem cell transplantation: Considerations for donors
169. Use of G-CSF to mobilise PBSC in normal healthy donors: An international survey
170. Blood stem cell procurement: Donor safety issues
171. An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor
172. Mutations in the gene for the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia
173. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy
174. Recombinant human granulocyte-macrophage colony-stimulating factor produces fever
175. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant granulocyte-macrophage colony-stimulating factor
176. GM-CSF therapy and capillary-leak syndrome
177. Preclinical and clinical evaluation of recombinant human macrophage colony-stimulating factor (rhM-CSF)